Role of CHOP and ER Stress in RGC Degeneration
About the Research Project
Program
Award Type
Standard
Award Amount
$90,000
Active Dates
April 01, 2007 - March 31, 2009
Grant ID
G2007062
Acknowledgement
Goals
These experiments seek to determine if inhibition of the stress induced response can reduce or prevent the loss of retinal ganglion cells. If successful, this work could help provide the basis for the development of new strategies for the diagnosis and treatment of glaucoma.
Summary
Glaucoma is a major cause of vision loss. It is the second most common cause of blindness worldwide. In glaucoma, decreased vision is caused by the injury and death of retinal ganglion cells (RGCs), the cells that transmit visual information from the eye to the brain. All current forms of glaucoma treatment (drugs, laser treatment, and surgery) act by lowering the pressure within the eye. Although pressure lowering can be helpful, RGC loss can continue even after pressure reduction. Greater understanding of the molecular mechanisms underlying retinal ganglion cell (RGC) loss will likely make possible the development of more effective diagnostic and treatment strategies. In the work proposed in this application we will explore the molecular mechanisms that actually induce the death of RGCs. In preliminary studies we have shown that a particular pathway, called the stress induced response, is activated in animal models of glaucoma. We propose to study this pathway in more detail, and determine if inhibition of the stress induced response can reduce or prevent the loss of RGCs.
Related Grants
National Glaucoma Research
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
National Glaucoma Research
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
National Glaucoma Research
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute